Obtains an exclusive worldwide license from Xoma to the chimeric pan-carcinoma monoclonal antibody ING-1, which is currently in preclinical evaluation for a number of types of cancer. Xoma will receive a technology access fee and royalties from future product sales. Sterling, which will conduct all further development work on ING-1, will also receive a nonexclusive license to certain Xoma genetic engineering technologies for cancer applications. Xoma says the move is its first in connection with an earlier decision to license some of its cancer-related drug development programs and concentrate on products for infectious diseases and immune disorders. While Xoma's initial product development efforts have been with murine antibodies, the company's 1989 acquisition of Ingene provided chimeric monoclonal antibody technology.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth